Klotho Neurosciences Soars 49.45% on Longevity Breakthrough

On June 10, 2025, Klotho Neurosciences experienced a remarkable surge, rising 49.45% in pre-market trading, marking a significant milestone for the biotechnology company.

Klotho Neurosciences has made groundbreaking advancements in longevity research, focusing on the Klotho gene. The company has secured exclusive worldwide licenses for s-KL protein technology, which builds on Professor Makoto Kuro-O's 1997 discovery linking Klotho blood levels to mammalian lifespan. Recent studies published in Molecular Therapy demonstrated that genetic overexpression of Klotho increased mouse lifespan by 30-40%, while the secreted form (s-KL) showed a 20% lifespan increase. The research revealed s-KL's potential in addressing age-related conditions including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis.

Klotho Neurosciences is planning to develop s-KL treatments focusing on neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. The company's strategic intellectual property position, with patents issued across the US, Europe, and China, strengthens their scientific credibility. Professor Kuro-O's involvement as a scientific advisor further enhances their research capabilities. The company's focus on targeting fundamental aging processes rather than just symptoms shows scientific sophistication, suggesting potential applications beyond neurodegeneration into broader anti-aging therapeutics.